Diasorin SpA (MIL:DIA) Other Financing: €0 Mil (TTM As of Dec. 2025)


MIL:DIA Diasorin SpA MIL:DIA
71 GF Score
Price €67.76
GF Value €90.16
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Diasorin SpA Other Financing?

Diasorin SpA MIL:DIA -3.14% 71 Other Financing is €0 Mil as of Dec. 2025. GuruFocus rates MIL:DIA with a GF Score™ of 71/100 and a GF Value™ of €90.16 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Diasorin SpA's Other Financing for the three months ended in Dec. 2025 was €0 Mil.

Diasorin SpA's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

Diasorin SpA Other Financing Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Other Financing Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 -0.00

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MIL:DIA
71GF Score
Diasorin SpA MIL:DIA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0 Mil mean?
Diasorin SpA (MIL:DIA) has a Other Financing of €0 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Diasorin SpA and its competitors.
Is Diasorin SpA's Other Financing too high?
Diasorin SpA's current Other Financing is €0 Mil. Overall, Diasorin SpA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Other Financing compare to TMO and DHR?
Diasorin SpA's Other Financing of €0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Diagnostics & Research company?
A good Other Financing depends on the Medical Diagnostics & Research industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Diasorin SpA and its competitors. Diasorin SpA's current Other Financing is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.16, compared to a current price of €67.76 — trading 24.8% below its estimated fair value. The current Other Financing is €0 Mil. Diasorin SpA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current Other Financing is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (MIL:DIA) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €67.76 is trading 24.8% below its estimated GF Value™ of €90.16. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for MIL:DIA:

  • Other Financing: €0 Mil
  • GF Value™: €90.16 vs. price of €67.76 (24.8% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
71GF Score

Get the complete analysis for MIL:DIA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.76
Price
€90.16
GF Value